Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor beta joining 1-4 (TRBJ1-4) is a J gene segment within the TCR β-chain locus. During T cell development in the thymus, variable (V), diversity (D), and joining (J) segments recombine to generate the full exon encoding the β-chain variable region of the T cell receptor. TRBJ1-4 contributes to the hypervariable complementarity-determining region 3 (CDR3) of the TCR, which is critical for antigen specificity[5][6][9]. This process is essential for producing the diverse repertoire of T cells capable of recognizing many different antigens presented by major histocompatibility complex (MHC) molecules[1]. TRBJ1-4 itself is not a receptor or protein—it is a genomic sequence incorporated into mature TCRs if selected during recombination[8].\n\nNote:\n- This is not a canonical protein, receptor, or enzyme target, but a gene segment.[5]\n- The presence of aliases referring to different segments (e.g., TRBJ14) suggests possible confusion or error.\n- It is not directly targetable nor does it possess a typical molecular classification of therapeutic proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor beta joining 1-4 (TRBJ1-4).